Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.38 USD
Change Today +0.03 / 1.28%
Volume 408.0K
AMPE On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 4:02 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

ampio pharmaceuticals inc (AMPE) Snapshot

Open
$2.37
Previous Close
$2.35
Day High
$2.38
Day Low
$2.25
52 Week High
03/18/15 - $9.01
52 Week Low
05/20/15 - $1.94
Market Cap
123.7M
Average Volume 10 Days
1.4M
EPS TTM
$-0.72
Shares Outstanding
52.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMPIO PHARMACEUTICALS INC (AMPE)

Related News

No related news articles were found.

ampio pharmaceuticals inc (AMPE) Related Businessweek News

No Related Businessweek News Found

ampio pharmaceuticals inc (AMPE) Details

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and decreasing vascular permeability. Its lead product candidates in development include Ampion, which is in Phase III clinical trial for osteoarthritis of the knee; and Optina that is in Phase IIb clinical trial for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

23 Employees
Last Reported Date: 02/24/15

ampio pharmaceuticals inc (AMPE) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $455.0K
Chief Financial Officer, Corporate Secretary ...
Total Annual Compensation: $143.5K
Chief Regulatory Affairs Officer
Total Annual Compensation: $255.0K
Chief Scientific Officer and Director
Total Annual Compensation: $305.0K
Compensation as of Fiscal Year 2014.

ampio pharmaceuticals inc (AMPE) Key Developments

Ampio Pharmaceuticals, Inc. Announces Positive Study Results on Optina for the Treatment of Diabetic Macular Edema

Ampio Pharmaceuticals, Inc. announced positive results of the OptimEyes trial for DME. The OptimEyes trial was a multiple site, randomized, placebo controlled, parallel, double masked study to evaluate the safety and efficacy of two doses of oral Optina (adjusted to body mass index-BMI) in adult patients with Diabetic Macular Edema (DME). The OptimEyes trial, with FDA guidance, was designed to include a wide variety of DME patients, some of whom had no therapeutic options and were progressing to blindness. Intraocular injections may have been contraindicated in these patients. Including patients not accepted in other trials of intraocular injections allowed to better understand the effect of oral Optina in improving visual acuity (measured as best corrected visual acuity-BCVA, eye chart) and reducing edema (as measured by optical coherence tomography-OCT) in all patients. The goal of the study was to assess the safety and efficacy of oral Optina, identify the patients who respond and the ideal dose. Orally administered Optina was extremely safe with no drug related serious adverse events. There were no differences in side effect rates between placebo and the Optina arms. Results for this group are as: Overall, 53% of patients included in the trial were refractory (unresponsive) to the approved intraocular injection therapies. These refractory patients showed a significant +6.2 letter improvement in visual acuity over the three month period of the study (P< 0.001). In the remaining 47% patients who were unable or unwilling to have eye injections, they showed a significant +3.1 letter improvement over the same period (p=0.04). The placebo group failed to achieve a significant increase in visual acuity in either of the subgroup of patients who were and were not refractory to intraocular injections over the same time period (+2.0 letters, p=0.20, +0.7 letters, p=0.72 respectively). In addition to showing significant improvements in visual acuity, the patients had a significant decrease in retinal swelling of 46 microns (p=0.003). Again, the placebo group failed to show a significant change in retinal swelling (-12 microns, p=0.47).

The Rosen Law Firm Files Securities Class Action Against Ampio Pharmaceuticals

The Rosen Law Firm announced that it has filed a class action lawsuit on behalf of purchasers of Ampio Pharmaceuticals, Inc. securities from January 13, 2014 through August 21, 2014, inclusive. The lawsuit seeks to recover damages for Ampio investors under the federal securities laws. According to the lawsuit, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the clinical research organization conducting the STEP Study lacked independence; (2) the trial drug supply for the STEP Study was shipped to clinical sites at lower temperatures than permitted by the drug specifications; and (3) as a result, of the foregoing, the company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Ampio Pharmaceuticals, Inc. Announces Resignation of Joshua R. Disbrow as Chief Operating Officer

On April 16, 2015, Joshua R. Disbrow resigned as Chief Operating Officer of Ampio Pharmaceuticals, Inc. in connection with the Merger (as defined below) to assume the role of Chief Executive Officer of Rosewind. On April 16, 2015, Luoxis Diagnostics, Inc. and Vyrix, each previously a subsidiary of Ampio, entered into an agreement and plan of merger by and among Rosewind, Luoxis, Vyrix, two major stockholders of Rosewind and two subsidiaries of Rosewind created solely for the purposes of the merger.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMPE:US $2.38 USD +0.03

AMPE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMPE.
View Industry Companies
 

Industry Analysis

AMPE

Industry Average

Valuation AMPE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,346.2x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 852.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMPIO PHARMACEUTICALS INC, please visit www.ampiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.